Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Denali Therapeutics Inc.

Get SEC filing alerts via email and in your feed for Denali Therapeutics Inc.

DNLI

Denali Therapeutics Inc.

About Denali Therapeutics Inc.

Denali Therapeutics Inc. develops innovative biotherapeutics targeting neurodegenerative and lysosomal storage diseases. Utilizing its proprietary TransportVehicle platform, the company enables large molecules, enzymes, antibodies, and oligonucleotides to cross the blood-brain barrier for CNS and systemic treatment. Its portfolio includes enzyme replacement therapies and gene-modulating agents for rare and common neurological disorders, leveraging biomarker-driven development and strategic collaborations.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Denali Therapeutics Inc.

1
1
Denali Therapeutics Inc. Denali Therapeutics Reports Q1 2026 Financial Results with $128.4M Net Loss

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Denali Therapeutics Inc. Denali Therapeutics Reports $512.5 Million Net Loss for 2025, Submits BLA for Tividenofusp Alfa

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Denali Therapeutics Inc. Denali Therapeutics Reports $126.9 Million Net Loss in Q3 2025, Increases R&D Investments

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Denali Therapeutics Inc. Denali Therapeutics Reports $124.1 Million Net Loss in Q2 2025, Increases R&D Investments

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Denali Therapeutics Inc. Denali Therapeutics Reports $132.97 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Denali Therapeutics Inc. Denali Therapeutics Reports Net Loss of $107.2M in Q3 2024, Cash Reserves Decrease to $1.28B

Via official filing (AI summary) | over 1 year ago | 0 comments